2024
Alzheimer’s disease is a major health concern. Recent FDA-approved therapies provide relief to Alzheimer’s patients at early disease stages. However, these therapies are associated with major side effects in Alzheimer’s patients carrying the APOE4 gene. Thus, it is important to investigate how brains function differently in APOE4 carriers compared to non-carriers. Here, we will investigate brain function in a mouse model expressing the human APOE4 gene. We will monitor neuronal activity using leading-edge technologies. We will also determine the sleep impairments that actively contribute to Alzheimer’s progression in the context of APOE4. These studies will provide a strong basis for future therapeutic development tailored specifically to Alzheimer’s patients with the APOE4 gene.